Last December, Capricorn Venture Partners, a Leuven, Belgium venture capital firm, held the first close of its health-tech fund, at €42m.
The Capricorn Health-tech Fund will focus on early to mid stage human health-technology companies in Europe.
Capricorn defines health-technology as any technology based product used for the prevention, the diagnosis or the treatment of diseases and medical indications in humans.
This includes subsectors such as biopharmaceutical and pharmaceutical drugs, vaccines, medical devices, medical imaging, diagnostics, (research) equipment, nutraceuticals and functional foods.
Investors in the fund include Dexia Insurance Belgium, FPIM (Federale Participatie- en Investeringsmaatschappij), PMV (Participatie-Maatschappij Vlaanderen), SRIW (Société Régionale d’Investissement de Wallonie), Quest for Growth, as well as a number of private investors and two universities.